Окислительный стресс – роль в патогенезе хронической сердечной недостаточности, возможности коррекции
https://doi.org/10.15829/1728-8800-2012-6-91-94
Аннотация
Сердечно-сосудистые заболевания (ССЗ) в течение многих лет являются лидирующей причиной смертности во всем мире. Согласно статистике Всемирной организации здравоохранения (ВОЗ), среди общей смертности в России смертность от ССЗ составляет 57%. В последние годы идут поиски новых маркеров ССЗ, которые могут улучшить диагностику и терапию этой обширной и прогностически неблагоприятной группы заболеваний. Значительные исследовательские усилия были направлены на выявление изменений в уровне маркеров окислительного стресса (ОС) и активности антиокислительных ферментов в качестве возможных механизмов, лежащих в основе развития ССЗ. Учитывая, что большое значение в последнее время придается плейотропным, в частности антиокислительным эффектам статинов, вопросы применения этого класса лекарств при хронической сердечной недостаточности (ХСН) активно обсуждаются медицинской общественностью в плане возможности их применения для лечения ХСН не только ишемической этиологии.
Об авторах
Л. О. ПалаткинаРоссия
аспирант кафедры пропедевтики внутренних болезней
О. Н. Корнеева
Россия
(контактное лицо) – врач-кардиолог
О. М. Драпкина
Россия
зав.отделением кардиологии УКБ№ 2
Список литературы
1. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. JACC 1998; 31: 1352-6.
2. Voyeykov V. L. Bio-physical and chemical aspects of aging and longevity. Successes of gerontology 2002; 9: 261. Russian (Воейков В.Л. Биофизико-химические аспекты старения и долголетия. Успехи геронтологии 2002; 9: 261).
3. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12: 1161-208.
4. Drоge W. Free radicals in physiological control of cell function. Physiol Rev 2002; 82: 47–95.
5. Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp. 1995; 61: 1–31.
6. McMurray J, Chopra M, Abdullah I, et al. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14: 1493– 8.
7. Higashi Y, Sasaki S, Nakagawa K, et al. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-62.
8. Zotova I.V., Zateyshchikov D. A., Sidorenko B. A. Synthesis of nitric oxide and development of atherogenesis. Cardiology 2002; 4: 58-67. Russian (Зотова И.В., Затейщиков Д.А., Сидоренко Б.А. Синтез оксида азота и развитие атерогенеза. Кардиология 2002; 4: 58-67.)
9. Chen H, Hu CJ, He YY, et al. Reduction and restoration of mitochondrial dna content after focal cerebral ischemia/reperfusion. Stroke 2001; 32: 2382-7.
10. Xu J, Lupu F, Esmon C. Inflammation, innate immunity and blood coagulation. Hamostaseol 2010; 1. 30: 5–9.
11. Iyer A, Fairlie D, Prins J, et al. Inflammatory lipid mediators in adipocyte function and obesity. Nature Rev Endocrin 2010; 2. 6: 71–82.
12. Buggerand H, Abel D. Mitochondria in the diabetic heart. Cardiovascular Research 2010; 2. 88: 229–40.
13. Pankuweit S, Ruppert V, Maisch B. Inflammation in dilated cardiomyopathy. Herz 2004; 8. 29: 788–93.
14. Moreno P, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. JACC 2004; 12. 44: 2293–300.
15. Seddon M, Looi H, Shah M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007; 93: 903–7.
16. Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 1995; 61: 1–31.
17. Seshiah PN. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406–13.
18. Sawyer DB. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379–88.
19. Ungvari Z, Csiszar A, Huang A, et al. High pressure induces superoxide production in isolated arteries via proteinkinase C-dependent activation of NAD(P)H oxidase. Circulation 2003; 108: 1253-8.
20. Cave AC, Grieve DJ, Johar S, et al. NADPHoxidase-derived reactive oxygen species in cardiac pathophysiology. Philos Trans R Soc 2005; 360: 2327–34.
21. Landmesser U, Dikalov S, Price S. et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitricoxidesynthase in hypertension. J Clin Invest 2003; 8. 111: 1201–9.
22. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 1996; 148: 291-300.
23. Mallat Z, Philip I, Lebret M, et al. Elevated levels of 8-iso-prostaglandin in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 97: 1536–9.
24. Tsutsui H, Ide T, Hayashidani S, et al. Greaters usceptibility of failing cardiacmyocytes to oxygen free radical-mediated injury. Cardiovasc Res 2001; 49: 103-9.
25. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997; 96: 509–16.
26. Willenbrock R, Philipp S, Mitrovic V, et al. Neurohumoral blockade in CHF management. J Ren Angiot Aldoster Syst 2000; 1: 24–30.
27. Takano H, Hasegawa H, Nagai T, et al. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies. Intern Med 2003; 42: 465–9.
28. Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 2009; 81: 449-56.
29. Siwik D, Pagano P, Colucci W. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol 2001; 1. 280: 53–60.
30. Higuchi Y. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 2002; 34: 233–40.
31. Thollon C, Iliou JP, Cambarrat С, et al. Nature of the cardiomyocyte injury induced by lipid hydroperoxides. Cardiovasc Res 1995; 30: 648–55.
32. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997; 272: 203–6.
33. Wilson JR. Exercise in tolerance in heart failure. Importance of skeletal muscle. Circulation 1995; 91: 559-61.
34. Gao WD, Liu Y, Marban E. Selective effects of oxygen free radicals on excitationcontraction coupling in ventricular muscle: implications for the mechanism of stunned myocardium. Circulation 1996; 94: 2597–604.
35. Valko M, Leibfritz D, Mazur M. Free radicals and antioxidants in normal physiological functions and human disease. Intern J Biochem Cell Biol 2007; 1. 39: 44–84.
36. Vassalle C, Pratali L, Boni C, et al. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clin Biochem 2008; 41: 1162-7.
37. Nordberg J, Arner E. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001; 31: 1287–312.
38. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154–60.
39. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: arandomised placebo-controlled trial. Lancet 2002; 360: 23–33.
40. Chopra M, McMurray J, Stewart J, et al. Free radical scavenging: a potentially beneficial action of thiol–containing angiotensin converting enzyme inhibitors. Biochem Soc Trans 1990; 18(6): 1184–5.
41. Сominacini L, Pasini A, Garbin U, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15(10): 891-5.
42. Pasini AF, Garbin U, Nava MC, et al. Effect of sulfhydryl and non–sulfhydryl angiotensin–converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20(4): 443–50.
43. Cipollone F, Fazia M, Iezzi A, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 12. 109: 1482–8.
44. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectine and soluble P-selectine levels in hypertensive patients. J Hypertens 2006; 24: 591-6.
45. Dandona P, Ghanim H, Brooks D. Antioxidant activity of carvedilol in cardiovascular disease. J Hyperten 2007; 4. 25: 731–41.
46. Mason PR, Kalinowski L, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005; 112: 3795-801.
47. Belenkov YuN, Privalova EV, Danilogorskaya YuA, et al. Oxidative stress at a chronic heart failure. Possibilities of pharmacological correction. Cardiol Cardiovasc Surg 2009; 1: 4-9. Russian (Беленков Ю.Н., Привалова Е.В., Данилогорская Ю.А., и. др. Оксидативный стресс при хронической сердечной недостаточности. Возможности фармакологической коррекции. Кардиол серд.-сосуд хир 2009; 1: 4-9.)
48. Aronov DM. Application of statins in cardiological practice. Аttend Phys 2006; 9: 40-4. Russian (Аронов Д.М. Применение статинов в кардиологической практике. Леч врач 2006; 9: 40-4.)
49. Wassman S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450—7.
50. Hussein O, Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low-density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11–8.
Рецензия
Для цитирования:
Палаткина Л.О., Корнеева О.Н., Драпкина О.М. Окислительный стресс – роль в патогенезе хронической сердечной недостаточности, возможности коррекции. Кардиоваскулярная терапия и профилактика. 2012;11(6):91-94. https://doi.org/10.15829/1728-8800-2012-6-91-94
For citation:
Palatkina L.O., Korneeva O.N., Drapkina O.M. Oxidative stress, its role in the pathogenesis of chronic heart failure, and potential methods of correction. Cardiovascular Therapy and Prevention. 2012;11(6):91-94. (In Russ.) https://doi.org/10.15829/1728-8800-2012-6-91-94